M. Brausi Et Al. , "Re: Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate-and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG," JOURNAL OF UROLOGICAL SURGERY , vol.2, no.1, pp.41, 2015
Brausi, M. Et Al. 2015. Re: Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate-and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG. JOURNAL OF UROLOGICAL SURGERY , vol.2, no.1 , 41.
Brausi, M., Oddens, J., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., ... Gontero, P.(2015). Re: Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate-and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG. JOURNAL OF UROLOGICAL SURGERY , vol.2, no.1, 41.
Brausi, Maurizio Et Al. "Re: Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate-and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG," JOURNAL OF UROLOGICAL SURGERY , vol.2, no.1, 41, 2015
Brausi, Maurizio Et Al. "Re: Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate-and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG." JOURNAL OF UROLOGICAL SURGERY , vol.2, no.1, pp.41, 2015
Brausi, M. Et Al. (2015) . "Re: Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate-and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG." JOURNAL OF UROLOGICAL SURGERY , vol.2, no.1, p.41.
@article{article, author={Maurizio Brausi Et Al. }, title={Re: Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate-and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG}, journal={JOURNAL OF UROLOGICAL SURGERY}, year=2015, pages={41} }